In the present work, the development of anti-nucleolin VHHs relied on a grafting strategy based on the nucleolin-binding 31-amino acid F3 peptide, which had previously demonstrated promising in vivo tumour targeting capabilities29,37–39. This evidence concerns the gene NUCLEOLIN and neoplasm.